Cite
APA Citation
Tripathy, D., Hortobagyi, G. N., Chan, A., Im, S., Chia, S., Yardley, D., Esteva, F. J., Hurvitz, S. A., Ridolfi, A., & Slamon, D. (n.d.). 166PPooled safety analysis of first-line ribociclib (RIB) plus endocrine therapy (ET) in HR+/HER2– advanced breast cancer (ABC). Annals of oncology, 30, . http://access.bl.uk/ark:/81055/vdc_100094055779.0x000039